Clinical Trials

105 enrolled 33 charts 2 FDA

Lymphoma, Mantle-Cell

NCT03070392 2026-03-17

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

378 enrolled 15 charts 1 FDA

Uveal Melanoma, Melanoma

NCT04484142 2026-03-17

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

137 enrolled 9 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04710576 2026-03-16

AGAVE-201

241 enrolled 11 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT03332017 2026-02-18

ROSEWOOD

217 enrolled 23 charts 1 FDA

Lymphoma, Follicular

NCT04711135 2026-02-12

NETTER-P

11 enrolled 14 charts 1 FDA

CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT02213926 2026-02-10

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

124 enrolled 10 charts 1 FDA

Lymphoma, Mantle-Cell

NCT04044768 2026-02-06

Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

52 enrolled 15 charts 1 FDA

Sarcoma

Sarcoma, Sarcoma, Synovial, Liposarcoma, Myxoid

NCT04744831 2026-01-14

DESTINY-CRC02

122 enrolled 21 charts 1 FDA

Colorectal Neoplasms

NCT02864992 2025-12-23

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

337 enrolled 13 charts 2 FDA

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT03105336 2025-12-23

ZUMA-5

159 enrolled 27 charts 1 FDA

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT01743131 2025-12-11

Abatacept as GVHD Prophylaxis Phase 2

186 enrolled 14 charts 1 FDA

Graft vs Host Disease, Neoplasms

NCT02360579 2025-12-09

LN-144

220 enrolled 15 charts 1 FDA

Melanoma

NCT04649359 2025-12-02

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

187 enrolled 14 charts 1 FDA

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04644237 2025-11-21

DESTINY-LUNG02

152 enrolled 22 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03011372 2025-11-18

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

47 enrolled 21 charts 1 FDA

Myeloid

Eosinophilia, Myeloproliferative Disorders

NCT03915951 2025-11-17

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

98 enrolled 18 charts 1 FDA

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT02060188 2025-11-06

CheckMate142

385 enrolled 17 charts 2 FDA

GastrointestinalOther solid neoplasm

Microsatellite Unstable Colorectal Cancer

NCT03568461 2025-10-07

ELARA

98 enrolled 9 charts 1 FDA

Lymphoma, Follicular, Recurrence

NCT04466891 2025-09-15

HERIZON-BTC-01

87 enrolled 25 charts 1 FDA

Biliary Tract Neoplasms, Gallbladder Neoplasms

NCT01784068 2025-09-10

ENESTfreedom

215 enrolled 7 charts 1 FDA

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03525678 2025-09-03

A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Participants With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody

221 enrolled 61 charts 2 FDA

Multiple Myeloma

NCT01698905 2025-09-02

ENESTop

163 enrolled 7 charts 1 FDA

MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03597295 2025-08-21

A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)

94 enrolled 18 charts 1 FDA

Squamous Cell Carcinoma of Anal Canal

NCT02924376 2025-08-14

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

147 enrolled 22 charts 2 FDA

Acrocephalosyndactylia, Cholangiocarcinoma

NCT03962543 2025-08-07

ReNeu

114 enrolled 25 charts 1 FDA

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

NCT03599713 2025-08-05

A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)

107 enrolled 16 charts 1 FDA

Carcinoma, Merkel Cell

NCT03295396 2025-07-28

ONC201 in Adults With Recurrent H3 K27M-mutant Glioma

73 enrolled 13 charts 1 FDA

Glioma

NCT03248492 2025-06-26

DESTINY-Breast01

253 enrolled 21 charts 1 FDA

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02601950 2025-06-22

A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma

267 enrolled 25 charts 2 FDA

Sarcoma

Sarcoma, Sarcoma, Synovial

NCT03505710 2025-05-30

DESTINY-Lung01

181 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03361748 2025-05-23

KarMMa

149 enrolled 29 charts 1 FDA

Multiple Myeloma, Recurrence

NCT03412565 2025-04-29

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

265 enrolled 21 charts 3 FDA

Multiple Myeloma

NCT03132636 2025-04-08

PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

138 enrolled 21 charts 1 FDA

Carcinoma, Basal Cell

NCT00753545 2025-02-03

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

265 enrolled 25 charts 1 FDA

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT02525692 2024-12-24

Oral ONC201 in Adult Recurrent Glioblastoma

84 enrolled 14 charts 1 FDA

Glioblastoma

NCT03640481 2024-12-12

Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

159 enrolled 25 charts 1 FDA

Bronchiolitis Obliterans Syndrome

NCT03043313 2024-11-26

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

117 enrolled 21 charts 1 FDA

Colorectal Neoplasms

NCT03206970 2024-10-26

Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

86 enrolled 16 charts 1 FDA

Lymphoma, Mantle-Cell

NCT03846427 2024-10-26

MAGNOLIA

68 enrolled 28 charts 1 FDA

Lymphoma, B-Cell, Marginal Zone

NCT02702414 2024-09-04

KEYNOTE-224

156 enrolled 17 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Hepatocellular

NCT03219333 2024-08-27

EV-201

219 enrolled 32 charts 2 FDA

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT03284424 2024-08-23

MK-3475-629

159 enrolled 16 charts 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Squamous Cell

NCT02395666 2024-08-06

Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission

140 enrolled 14 charts 1 FDA

Neuroblastoma

NCT02000427 2024-05-28

Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia

45 enrolled 24 charts 1 FDA

LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02445248 2024-04-18

JULIET

115 enrolled 22 charts 1 FDA

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02414139 2024-03-20

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

373 enrolled 34 charts 3 FDA

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT02435849 2024-02-13

ELIANA

80 enrolled 39 charts 1 FDA

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03483103 2023-12-20

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

74 enrolled 43 charts 1 FDA